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In the treatment of hepatitis C, direct-acting antivirals (DAA) are highly efficient and well tolerated with a series of DAA 
combinations available for treatment. A sensitive high-performance liquid chromatography-tandem mass spectrometry 
(UPLC-MS/MS) method has been developed and validated for the simultaneous quantification of Sofosbuvir (SOF) and 
Daclatasvir (DAC) in human plasma. Sofosbuvir D6 (SOF D6) and Daclatasvir 13C2
2H6 (DAC 
13C2
2H6) are used as internal
standard (IS). Quantification for both the analytes has been attained with MS-MS detection in positive ion mode using an 
Acquity UPLC system (Waters) equipped with Waters Xevo TQ MS system with a Gemini NX 5µ C18 (50 × 2.0mm) 
(Phenomenex) column, and a gradient mobile phase consisting 5 mM Ammonium Formate buffer: Acetonitrile at a flow rate 
of 0.300 mL/min is used as mobile phase to separate the analytes and detection is performed by electrospray ionization 
technique using the mass spectrometer. Full validation is performed for bio-analytical methods with respect to linearity, 
precision, accuracy, selectivity, carry-over, stability and dilution integrity. Linearity is obtained over a concentration range 
of 10.002 -3000.488 and 10.004 -3001.218 ng mL-1 for SOF and DAC respectively by applying weighted least-squares 
linear regression method (1/x2). The developed method was applied successfully in bioequivalence and/or clinical studies in 
48 male subjects for the simultaneous quantification of SOF and DAC. 
Keywords: Bioequivalence, Daclatasvir, Good clinical practice, High performance liquid chromatography, Liquid 
Chromatography, Lower limit of quantification, Mass Spectrometry, Sofosbuvir 
The significant efforts in field of HCV treatment has 
led to the discovery of new direct-acting antivirals, 
with better safety profile and improved antiviral 
potency
1
. In an approximation 170 million people 
worldwide are effected by chronic infection with 
hepatitis C virus (HCV) leading to cirrhosis and 
hepatocellular carcinoma. In the United States HCV-
related deaths are increased as compared to human 
immunodeficiency virus (HIV) infection
2
. For chronic 
HCV infection approximately 40% of patients with 
genotype 1 infection and 75% of patients infected 
with genotype 2 or 3 had sustained virologic response 
after treatment with Peginterferon alfa–ribavirin
3,4
. 
The HCV NS5A replication complex inhibitor DAC 
is highly potent against six major HCV genotypes (1a, 
1b, 2a, 3a, 4a, 5a)
5,6
, with a pharmacokinetic profile 
obtained by once-daily dosing. The other HCV NS5B 
polymerase inhibitor SOF administered once daily 
orally has a good safety profile
7
. Both DAC and SOF 
have potent antiviral activity and broad genotypic 
coverage and are administered orally once daily. 
In treatment-naïve patients with HCV genotype 1, 2, 
or 3 the combination of DAC 60 mg once daily + SOF 
400 mg once daily (with or without lead-in) ± weight-
based ribavirin for 24 weeks was associated with high 
rates of sustained virologic response including 
patients showing no response to telaprevir or 
boceprevir therapy
8
. In both untreated and treated 
genotype 3-infected patients without cirrhosis 
combination of DAC with SOF for 12 weeks achieved 
high sustained virological response (SVR) rates
9
. 
Rational design of pharmacokinetic studies in humans 
is an essential component to determine the optimal 
dose and provide initial evaluation of efficacy on a 
therapeutic target. In this context measuring plasma 
drug concentration using bioanalytical techniques is 
an appropriate tool to understand drug-drug 
interactions and perceive the pharmacokinetic and/or 
pharmacodynamic properties of small molecules. 
Previously bioanalytical assays using LC-MS/MS 
have been developed for other DAA's orfor DAC and 
SOF separately or in combination
10-18
, here we 
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developed and fully validated a bioanalytical method 
for the quantification of both DAC and SOF. The well 
validated method was further used to evaluate the 
bioequivalence of My Hep DVIR
TM
(DAC/SOF) 60 
mg /400 mg comprimes pellicules (tablets) of Mylan 
laboratories limited, India with daklinza ™ (DAC) 
tablets 60 mg (Bristol-Myers Squibb Company, 
Princeton, NJ 08543, USA) and Sovaldi® (SOF) 400 
mg film-coated tablets (Gilead sciences international 
ltd. Cambridge CB 216GT United Kingdom), under 
fasting conditions in 48 normal healthy adult human 
subjects. The developed model is simple, sensitive, 
selective, efficient, and validated and is reliable for 
the determination of DAC & SOF and ensures precise 
& accurate for the determination of DAC & SOF. 
Figure 1 depicts the chemical structure of Sofosbuvir 
and Daclatasvir. 
 
Experimental Section  
The reference samples of DAC (99.2%) and SOF 
(99.4%) were obtained from Mylan laboratories ltd. 
and DAC-
13
C2D6 (93.25%) and SOF-D6 (96.20%) 
were obtained from Diacel chiral technologies. The 
Milli Q water purification system procured from 
Millipore (Bangalore, India) was used to prepare 
water for the LC-MS/MS analysis. Formic acid 
(suprapure grade) was purchased from Merck. 
Acetonitrile (HPLC grade) was purchased from Fisher 
or J.T. Baker (Phillipsburg, USA) while HPLC grade 
methanol was purchased from Merck, Fisher or J.T. 
Baker (Phillipsburg, USA). Ammonium Formate of 
grade GR was purchased from Sigma Aldrich. Human 
plasma sample for the control was obtained from 
Deccan’s Pathological Lab’s (Hyderabad, India). 
 
LC–MS system and conditions  
An Acquity UPLC system (Waters) equipped with 
Waters Xevo TQ MS system consisting of a Gemini 
NX 5µ C18 (50 × 2.0mm) (Phenomenex), a pump 
(Acquity binary sample Manager, Waters), and an 
auto sampler (Acquity sample manager) were used for 
the study. The injection volume (2 µL) for the 
processed samples were injected into the column, kept 
at ambient temperature (40 ± 5C). The separation  
of the analytes wasperformed by using agradient 
mobile phase (5 mM Ammonium Formate buffer: 
acetonitrile) delivered at a flow rate of 0.300 mL/min. 
Electrospray ionization mode was selected for 
ionization of the analytes in the mass spectrometer. 
The positive ion mode was selected for quantification 
of both analytes and the internal standards with MS-
MS detection using a Waters Xevo TQS system. The 
desolvation temperature was set to 500C, desolvation 
gas flow rate at 1000(L/Hr) and capillary voltage at 
3.50 KV. The ion spray voltage was set at 5500 V. 




H6 was set 
to 30V while for SOF and SOFD6 it was set to 25V. 
The collision energy for DAC and SOF were  
50 and 12 KV respectively. The multiple-reaction 
monitoring mode (MRM) was used for the detection 
of the ions by monitoring the parent ionm/z 739.28 
precursor ion to the m/z 339.20 for DAC, parent ion 




H6, and parent ion m/z 530.27 precursor ion to 
the m/z 243.10 for SOF, parent ionm/z 536.23 
precursor ion to the m/z 243.06 for SOF D6 
respectively. Analysis of the data obtained was 
processed by Mass Lynx 4.1 software. 
 
Stock solutions 
Stock solutions of DAC (1000.000 µg/mL) and 
SOF(1000.000 µg/mL) were prepared by dissolving 
5.000 mg of DAC and SOF in 5.00 mL of Milli Q 
water and methanol respectively. DAC 
13
C2D6 and 
SOF D6 stock solutions were prepared by dissolving 
in methanol at 400.00 µg/mL for both the IS.  
The DAC intermediate solutions 1 (DAC1) of 
concentration 250.00 µg/mL was prepared by using 
500 µL of DAC stock solution (1000.000 µg/mL) and 
made the volumeto 2 mL by using diluent [methanol 
and water (60:40%, v/v)]. The DAC intermediate 
solutions 2 (DAC2) of concentration 25.00 µg/mLwas 
prepared by using 200 µL DAC Intermediate Solution 
(250.000 µg/mL) and made the volume to 2 mL by 
using diluent [methanol and water (60:40%, v/v)]. 
 
 
Fig. 1 — Chemical structure of (A) Daclatasvir (DAC) (B) Sofosbuvir (SOF). 
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The SOF intermediate solution 1 (SOF1) of 
concentration 100.00 µg/mL was prepared by using 
500 µL of SOF stock solution (1000.000 µg/mL) and 
made the volume to 5 mL by using diluent [methanol 
and water (60:40%, v/v)]. Internal Standard Working 




H6 (5.000 µg/mL) and SOF D6 
(10.000 µg/mL) was prepared by dissolving 
respective stock (625 µL of DAC, 1250 µL of SOF) 
solutions in methanol and water (60:40) in a 50 mL 
volumetric flask. The preparation of working 
solutions with different concentrations was done by 
dilution of intermediate solutions [Diluent: methanol 
and water (60:40%, v/v)]. 
 
Sample pretreatment 
Aliquot of human plasma sample (100 µL) was 




H6, 5.000 µg/mL+SOF D6 10.000µg/mL) and 
vortexed for few seconds. To this, 100 µL of 1.0% 
Formic Acid extraction additive was added and 
vortexed for few seconds and kept aside for solid 
phase extraction (SPE).  
In the SPE procedure the cartridges (Strata-X, 30 
mg, 1cc) were conditioned and equilibratedwith 1mL 
of methanol followed by 1mL of Milli-Q water. The 
spiked plasma samples of volume 225 µL (100 µL 
aliquot of human plasma +25 µL of Working internal 
standard +100µL of 1.0% Formic Acid extraction 
additive) were loaded into cartridge and washed twice 
with 1.0 mL of Milli-Q/HPLC grade water followed 
by elution with 0.5 mL methanol. To the elute 0.5 mL 
of reconstitution solution [(Acetonitrile: 5mM 
Ammonium formate, 50:50, v/v): Methanol, 50:50, 
v/v], was added, vortexed and loaded into the UPLC 
vial. The injection volume of 2.0 µL was set for the 
chromatographic system. The developed method was 
validated on different parameters such as linearity, 
selectivity, sensitivity, precision and accuracy, 
recovery, matrix effect, stability, and dilution 
integrity. 
 
Calibration curves and limit of quantitation 
This assay was validated with a standard curve 
range of 10.004 to 3001.218 ng/mL for DAC and 
10.002 to 3000.488 ng/mL for SOF. The standard 
curve consisted of nine non-zero calibration 
standards, along with matrix blanks (with and without 
the addition of IS). The lowest concentration standard 
(10.004 ng/mL or DAC and 10.002 ng/mL for SOF) 
defined the lower limit of quantitation (LLOQ) for the 
assay, while the highest standard concentration 
(3001.218 ng/mL for DAC and 3000.488 ng/mL  
for SOF) defined the upper limit of the assay 
(ULOQ).Linearity is defined as the square of the 
correlation coefficient (r) obtained from weighted 
linear regression of peak area ratio (analyte/internal 
standard) versus concentration. The criterion for 
acceptable linearity is r ≥ 0.99. All validation standard 
curves used for accuracy and precision determinations 
surpassed this limit with r values of greater than 0.99. 
In any batch 75% of the standards samples and 67% 
of the QC samples (50% at each level should meet the 
acceptance criteria) were required to have an accuracy 
percentage deviation within ± 15% whereas for the 
LLOQ samples the accuracy percentage deviation 
should be within ± 20%. 
 
Selectivity, Matrix Effect, Recovery and Carry Over 
The selectivity experiment was performed 
usingfourteen different blank plasma lots (8 normal, 2 
(1.0 %) Haemolysed, 2 (2.0%) Haemolysed & 2 
lipemic) and the responses of the blank plasma lots 
were compared to the respective LLOQ standard 
mean area of DAC, SOF and IS. 
 To evaluate the matrix factor six lots (4 Normal, 1 
Haemolysed & 1 Lipemic) of interference free blank 
matrix from individual donor were taken, processed in 
triplicate from each lot and extracted according to the 
analytical method procedure. The post extracted LQC 
& HQC samples were obtained by spiking the analyte 
and IS into the extracted blank plasma and compared 
with12 aqueous (without matrix) samples (6 LQC & 6 
HQC). The matrix factor was determined by 
calculating the ratio between the peak area of post 
extracted to the mean peak area of unextracted 
samples for each lot. Additionally, IS normalized 
matrix factor was also determined by calculating the 
ratio of matrix factor of analytes by matrix factor of 
IS at each lot of matrix.The recovery percentage of 
DAC & SOF was estimated by analyzing the mean 
peak area of extracted versus unextracted LQC, 
M1QC, M2QC and HQC samples for DAC & SOF 
along with the IS (DAC and SOF -5.000 µg/mL and 
10.000 µg/mL respectively). 
 
Accuracy and Precision  
The intra-assay precision and accuracy of the 
method was assessed by analyzing 6 QC replicates 
each of the LLOQQC, LQC, M1QC, M2QC and HQC 
in 4 sets along with 4 sets of calibration curves 
samples for DAC and SOF.The inter-assay precision 
and accuracy of the method was also determined by 
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analyzing 6 QC replicates each of the LLOQQC, 
LQC, M1QC, M2QC and HQC in 4 sets along with 4 
sets of calibration curves samples for DAC and SOF. 
The acceptance criteria for the calibration curve 
correlation coefficient (r
2
) were set to be >0.98 and 
the obtained concentration values in the inter-day and 
intra-day assay for both accuracy and precision for 
LQC, M1QC, M2QC and HQC samples should be 
within ±15% of the nominal concentration and <15% 
RSD, and within ±20% of the nominal concentration 
and <20% RSD for LLOQ samples. 
 
Ruggedness 
The ruggedness experiment was evaluated by 
processing one P&A batch by different analyst and 
samples of one P&A batch was reinjected using 
different column of same make and specification.  
The experiment was performed by using nine  
non-zero calibration standards, along with matrix 
blanks calibration curve standard and 6 replicates of 
quality control samples (High (HQC), Medium 
(M1QC and M2QC) and low (LQC) ). The calculation 
of the concentrations were performed for the standard 
and quality control samples to determine the precision 
and accuracy of the experiment. 
 
Dilution integrity 
The dilution integrity experiment was performed 
using six replicates of 5-fold dilution and 10 fold 
dilution of the ULOQ samples and concentrations 
were determinedusing the freshly spiked calibration 
curve samples. The obtained concentrations were 
compared with nominal concentrations to findif 
samples with concentrations higher than the ULOQ 
could be suitably determined by dilution with blank 
matrix. 
 
Stability and re-injection reproducibility 
The stability experiments for the analyte in matrix 
(plasma stability) and stock solutions were performed 
under different stability conditions to prove the 
stability of the analyte during the study sample 
analysis condition. The plasma stability was 
conductedby using bulk spiked samples where the 
accuracy of six replicates of LQC and HQC were 
evaluated immediately after preparation. The 
autosampler stability, bench top stability, reinjection 
stability, wet extract stability, freeze thaw stability 
were performed by using six replicates of bulk spiked 
LQC and HQC samples. The stability of samples was 
accepted if assay values were within the limits of 
accuracy (85-115%) and precision within ≤15% RSD. 
Pharmacokinetic study design 
A randomized, balanced, two-treatment, four-
period, two-sequence, single-dose, full replicate, 
crossover oral bioequivalence study was planned as 
per the ICH GCP guidelines. Bioequivalence study 
was conducted on 48 male subjects under fasting 
conditions. In order to minimize the possibility of a 
carry-over effect, a minimum washout period of at 
least 15 days was selected for the study. In this study, 
the pharmacokinetic profile of the test product (A) 
DAC/SOF tablets 60 mg/400 mg was characterized 
relative to that of the reference products DAC and 
SOF, 60 mg and 400 mg given as separate dose to 
assess bioequivalence. Being a bioequivalence study 
with a crossover design, each subject act as his own 
control. Therefore, no control group was required for 
the study. The ethics committee approved the protocol 
and the volunteers provided with informed written 
consent. During each study period, 29 blood samples 
were collected. Blood samples were collected within 
1.50 minutes prior to dose administration (0.00 hour) 
and after dose administration at study hours 0.083, 
0.166, 0.25, 0.33, 0.50, 0.66, 0.83, 1.00, 1.25, 1.50, 
1.75, 2.00, 2.33, 2.66, 3.00, 3.50, 4.00, 4.50, 5.00, 
5.50, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 
and 48.00 hours in K3-EDTA vacutainer collection 
tubes (BD, Franklin, NJ, USA). The plasma samples 
were collected and stored at –70 ± 10C until use.  
The internal standard (IS) was spiked in plasma 
samples and extraction of both the analyte and IS was 
performed following the extraction procedure.  
The subject sample analysis was performed along 
with standard samples (calibration curve standards) 
and different level of QC samples (LQC, M1QC, 
M2QC and HQC) taken in triplicate. 
 
Results and Discussion 
 
LC-MS specification 
During method development for the simultaneous 
quantification of DAC and SOF; different 
chromatography and mass detection parameters were 
optimized to improve the analyte chromatograms and 
sensitivity of the method. The tandem mass 
spectroscopy due to its high sensitivity and selectivity 
is a unique analytical tool for pharmacokinetic 
studies. A better response for both the analyte and  
IS was obtained in the positive ionization mode and 
the MRM parameters were further optimized to 
increasethe analyte and IS response. The MS/MS 
system 
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The specified mass for the analyte in the first 
quadrupole (Q1) is the precursor ion that collides with 
the in-quadrupole collision cell (Q2) with the collision 
gas, and by collision-induced dissociation (CID) 
undergoes further fragmentation. The structural 
information of the resulting daughter ions from the 
fragmentation is detected by a third quadrupole mass 
analyzer (Q3).To obtain the best selectivity multiple 
reaction monitoring scanning mode was used. The 
mass spectrometry specification for DAC and SOF 
and the respective internal standards are mentioned in 
Table 1. For bestretention, peak intensity and less 
chromatographic run time the chromatographic 
conditions, were optimized by changing the 
composition of the mobile phase by several 
trials.Gemini NX (5µC18 50 × 2.0mm, Phenomenex) 
gave good peak shape and response even at lowest 
concentration level for both the analytes and IS. The 
gradient mobile phase with different composition of  
5 mM Ammonium Formate buffer: Acetonitrile was 
delivered into the electrospray ionization chamber of 
the mass spectrometer at a flow rate of 0.300 mL/min. 
The retention time of DAC and SOF were 2.15 and 
1.40 mins respectively and for the internal standard 
(DAC 
13
C2D6 and SOF D6) it was 2.12 and 1.35 mins 
respectively allowing a run time of 5.00 min. For both 
the analytes and respective IS the elution time frame 
variation was selected to be ± 30 secs. 
 
Sample preparation 
The extraction procedure for the analyte was 
checked for both liquid–liquid extraction (LLE) and 
solid phase extraction (SPE) and the results showed 
better recovery and low matrix effect for extraction of 
the drug and IS was obtained in the SPE technique. 
The auto sampler wash solution having a 
composition of 50% Acetonitrile/water was optimized 
to prevent carry over effect. The extraction buffer of 
100 μL of 1% formic acid was added to the plasma 
samples to extract the analyte and the IS. The analyte 
in the human plasma was detected with good accuracy 
and prediction by the optimized extraction procedure. 
 
Calibration curves and limit of quantitation 
This assay was validated with a standard curve 
range of 10.004 to 3001.218 ng/mL for DAC and 
10.002 to 3000.488 ng/mL for SOF. The standard 
curve consisted of nine non-zero calibration 
standards, along with matrix blanks (with and without 
the addition of internal standard). The lowest 
concentration standard (10.004 ng/mL or DAC and 
10.002 ng/mL for SOF) defined the lower limit of 
quantitation (LLOQ) for the assay, while the standard 
with the highest concentration (3001.218 ng/mL for 
DAC and 3000.488 ng/mL for SOF) defined the upper 
limit of the assay (ULOQ).The weighing factor 
selected was 1/x
2
. The preparation of the calibration 
curve (CC) standard samples were done by spiking 
appropriate volume of the working solutions (20 µL 
of DAC and 20 µL of SOF), in 960 µL of control 
human plasma resulting in final concentrations of 
10.004, 20.008, 50.020, 250.102, 600.244, 1200.487, 
1800.731, 2501.015, 3001.218 ng/mL for DAC, and 
10.002, 20.003, 50.008, 250.041, 600.098, 1200.195, 
1800.293, 2500.407 and 3000.488 ng/mL for SOF. 
The QC samples were prepared at of 9.999 (LLOQ), 
29.996 (LQC), 299.959 (M2QC), 1499.796 (M1QC), 
2259.693 (HQC) and 11998.371 (DQC) ng/mL for 
DAC and 10.012 (LLOQ), 30.035 (LQC), 300.347 
(MQC-2), 1501.735 (M1QC), 2262.614 (HQC) and 
12013.882 (DQC) ng/mL for SOF in blank plasma. 
The prepared plasma samples were kept at  
−70 ± 10°C. The criterion for acceptable linearity is  
r ≥ 0.99. All validation standard curves used for 
accuracy and precision determinations surpassed this 
limit with r values of greater than 0.99. 
Table 1 — Mass spectrometry specification for DAC and SOF and the respective internal standards. 
Time(min) Flow rate (per mL/min.) % Pump A 
(Acetonitrile) 
% Pump B 
(5 mM Ammonium formate buffer) 
0.00 0.300 35 65 
0.30 0.300 35 65 
1.25 0.300 43 57 
1.50 0.300 50 50 
1.90 0.300 50 50 
2.00 0.300 90 10 
3.50 0.300 90 10 
3.75 0.300 35 65 
5.00 0.300 35 65 
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Selectivity, matrix effect, recovery and carry over 
The developed method was selective as no 
significant interference was observed in any plasma 
lots (normal, lipemic, hemolyzed) for DAC, SOF and 
their respective IS. The matrix effect was examined to 
determine the ion suppression/enhancement on the 
ionization of the analytes and to make sure that 
selectivity, precision, and sensitivity are not affected 
by the matrix. For matrix effect no significant 
interference was observed at the RT of both the 
analytes as the % CV of IS normalized matrix factor 
for DAC and SOF was below 4% for both HOC  
and LQC level that was within acceptance criteria.  
(Table 2). 
The absolute recovery for DAC ranged from 79.76 
to 86.18 % while for SOF it ranged from 87.54 to 
90.70 %. For DAC-13C2D6 and SOF-d6 the recovery 
rates are 81.58 and 84.92% respectively. The mean 
recovery values were approximately ≥ 83% for DAC 
and ≥ 89% for SOF respectively. In case of both the 
analytes and their respective IS the difference in the 
recovery %CV across each QC level was within  
15%. (Table 2). The developed method showed no 
significant injector carry over for the analyte and IS. 
Accuracy and precision  
The inter- and intraday precision (%CV) and 
accuracy (% nominal value) of the method was 
determined by considering three batches having six 
replicates of quality controls samples at five different 
concentrations (LLOQQC, LQC, M1QC, M2QC and 
HQC) levelsand the results are summarized in 
Table 3. The accuracy was expressed as mean % 
nominal valueand was evaluated by considering the 
observed percentage deviation of mean from the 
theoretical spiked values. In both DAC and SOF 
across all QC levels the mean % nominal values were 
in range of 85-115% and %CV was less than 15% and 
met the acceptance criteria. Precision expressed as 
relative standard deviation (RSD) for the intra-day 
and inter day experimentswere below the acceptable 
limit of 15% at LQC, M1QC, M2QC and HQC levels, 
whereas for LLOQQC it was below 20%. The 
acceptable precision, accuracy result indicated the 




The ruggedness of the developed method was 
evaluated using different column and different analyst 
Table 2 — Matrix effect and recovery for DAC, SOF, DAC-13C2D6 and SOF-d6. 
Analyte Level %CV of IS-normalized matrix factor Recovery (%)/CV (%) Mean recovery 
DAC HQC 0.60 86.18/5.19 83.05 
M1QC - 82.28/6.03 
M2QC - 79.76/5.53 
LQC 1.30 83.97/11.61 
SOF HQC 0.74 90.70/6.78 89.24 
M1QC - 89.38/8.40 
M2QC - 87.54/7.85 
LQC 0.34 89.35/12.97 
DAC-13C2D6 - - 81.58/7.13 - 
SOF -d6 - - 84.92/9.84 - 
 
Table 3 — Precision and accuracy results for DRV and RTV. 
Precision and accuracy of DAC 
Nominal concentration in 
ng/mL 
Intra-day (n=6) Inter-day (n=24) 
Mean CV (%) Accuracy (%) Mean CV (%) Accuracy (%) 
HQC(2259.693) 2305.502 1.79 102.02 2259.668 1.91 99.99 
M1QC(1499.796) 1537.209 2.95 102.49 1547.629 1.76 103.19 
M2QC(299.959) 302.339 2.94 100.79 304.723 1.88 101.59 
LQC(29.996) 30.118 3.03 100.41 30.397 2.53 101.34 
LLOQQC(9.999) 9.913 1.42 99.14 10.099 4.93 101.00 
Precision and accuracy of SOF 
HQC(2262.614) 2272.828 0.95 100.45 2238.989 1.59 98.95 
M1QC(1501.735) 1550.380 3.55 103.23 1597.486 2.50 106.37 
M2QC(300.347) 320.313 2.44 106.65 325.724 1.67 108.45 
LQC(30.035) 30.483 1.92 101.49 30.537 1.66 101.67 
LLOQQC(10.012) 10.207 2.84 101.95 10.238 3.09 102.26 
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by using calibration curve standard and 6 replicates of 
quality control samples at five different concentration 
levels (LLOQQC, LQC, M1QC, M2QC and HQC). 
For accuracy, the quality controls samples showed  
the mean % nominal value within 85-115% for all 
analytes. 
The precision for ruggedness experiments were 
below the acceptable limit of 15% at LQC, M1QC, 
M2QC and HQC levels, whereas for LLOQQC it was 
below 20%. The ruggedness experiment for different 
column was performed byreinjecting samples of one 
P&A using a different column of similar make and 
specification. The ruggedness experiment for DAC & 
SOF is presented in Table 4. 
 
Dilution integrity 
The dilution integrity of the assay was performed  
at 5 times dilution and ten times dilutionon a 
concentration approx. 4 times ULOQ samples in six 
replicate and were calculated against freshly spiked 
calibration curve and compared with nominal 
concentrations. The result was within the acceptance 
criteria and is represented in Table 5. 
 
Reinjection reproducibility and stability  
The QC samples from the P&A batch was used to 
evaluate the partial reinjection reproducibility 
experiment. The QC samples were kept in the  
auto sampler for approx. 12 h 35 min at 5°C, and 
reinjected. The precision and accuracy of the samples 
were determined after reinjection. The concentration 
of both DAC and SOF after reinjection experiment 
showed no significant variability in auto sampler at 
5°C (approx. 12 h 35 min). 
The samples of the P&A batch were reinjected 
after keeping in the auto sampler for approximately 
29 h 7 min to evaluate the whole batch reinjection 
reproducibility experiment for the whole batch after 
the initial analysis and determinedfor precision and 
accuracy by calculating the concentrations of the 
analyte. Both the analytes (DAC & SOF) showed 
reproducible concentration after reinjection and were 
found to be stable in autosampler for approx. 29 h 
7 mins.  
The short term and long term stock and working 





SOF-D6 was found to be stable for 07 h 30 min and 
11 days in Milli Q Water, methanol & methanol: 
water (60:40) respectively in the refrigerator at  
0-10ºC. In order to evaluate the bench top stability 
stored QC samples (6 HQC and 6 LQC) were 
retrieved and kept for 27 h 16 minat room temperature 
Table 4 — Ruggedness experiment for DRV and RTV. 
 LLOQ QC LQC M2QC M1QC HQC 
DAC (Different analyst) 
Mean 10.198 30.564 305.221 1557.403 2266.78 
Accuracy 101.9902 101.8936 101.7542 103.841 100.3136 
%CV 4.18 2.01 0.95 0.66 1.14 
DAC (Different column) 
Mean 10.547 30.752 302.221 1539.695 2222.946 
Accuracy 105.4805 102.5203 100.7541 102.6603 98.37381 
%CV 6.43 3.20 1.14 1.41 1.09 
SOF (Different analyst) 
Mean 10.171 30.389 326.476 1607.613 2223.178 
Accuracy 101.72 101.31 108.84 107.19 98.38 
%CV 3.22 0.88 0.71 0.44 0.88 
SOF (Different column) 
Mean 10.542 30.808 326.063 1609.289 2196.014 
Accuracy 105.43 102.71 108.70 107.30 97.18 
%CV 2.17 2.13 0.88 1.03 0.58 
 
Table 5 — Dilution integrity results for DAC and SOF. 
Analyte QC level Dilution factor: 5 Dilution factor: 10 
 Mean CV % Bias Mean CV % Bias 
DAC DQC* 12167.357 2.39 1.41 11954.477 1.86 -0.37 
SOF DQC* 11473.804 2.99 -4.50 13612.606 2.03 13.31 
*For DAC the DQC concentration is 11998.371 ng/mL. For SOF the DQC concentration is 12013.882 ng/mL. 
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and compared with freshly processed comparison  
6 LQC and 6 HQC samples along with freshly 
prepared calibration standards.The mean % change in 
concentrations were calculated to determine the 
stability period that was approx. 27 h 16 min at room 
temperature for DAC & SOF. The results are 
presented in Table 6. 
The dry ice stability (coolant) was used to 
determine the stability of DAC and SOF during 
transportation in the biological matrix. The dry ice 
stability was determined by keeping 6 sets of LQC 
and HQC for approximately 69 h 51 min in dry ice 
after which the stability QC samples (6 HQC and 6 
LQC) were processed and analyzed with freshly 
processed QC (LQC and HQC samples) and freshly 
prepared calibration standards. The results presented 
in Table 6. The dry ice stability of DAC&SOF were 
found to be approx. 69 h 51 min that indicates the 
stability time during shipment of the clinical samples.  
The post extracted refrigerator stability in matrix 
was performed to check the stability of analytes after 
adding reconstitution solution to the processed 
samples and storing the samples in refrigerator for 
desired time duration at 0-10C. The QC samples 
consisting of 6 LQC and 6 HQC were retrieved from 
deep freezer, and after sample processingand 
reconstitution were stored for approx. 27 h in 
refrigerator at 0-10C. The samples were retrieved 
after specified time and compared along with freshly 
processed samples (LQC and HQC) and freshly 
prepared calibration standard samples. The results 
presented in Table 6. These results showed both the 
analytes DAC & SOF were stable during 27 h of 
storage in the refrigerator at 0-10C. The freeze and 
thaw stability samples were determined by preparing 
six aliquots of LQC and HQC levels and stored at set 
temperature -70C and -20C and for each 
concentration (LQC and HQC) 5 freeze and thaw 
cycles (stability samples) were performed. These 
freeze and thaw subjected samples were processed 
and compared with LQC and HQC samples (freshly 
processed comparison samples) and freshly prepared 
calibration standards. The mean % change in 
concentrations was calculated and after 5 cycles DAC 
& SOF were found to be stable. Results are presented 
in Table 6. 
 
In-injector Stability in Auto Sampler at 5ºC  
The autosampler stability was determined by using 
six replicates of LQC and HQC (3 sets at each level). 
The processing of the first set of QC samples after 
kept in autosampler at 5C after 80 h 6 min was 
compared with the second set of samples and with 
freshly prepared calibration standard samples. The 
mean % change in concentrations was calculated to 
determine the stability period. For both DAC and SOF 
at 5°C the stability of LQC & HQC samples was 
found to be approx. 80 h 6 min. Results are presented 
in Table 6. In whole blood stability six replicates of 
whole blood at Low and High QC level (Stability 
samples) were spiked and kept at the working bench. 
After a period of 02 h 05 min spiking, six aliquots 
of whole blood at low and high QC (comparison 
samples) were aliquoted separately. The plasma was 
separated from both the stability and comparison 
Table 6 — Stability study results for DAC and SOF. 
Storage period and storage condition QC level DAC SOF 
  Mean CV (%) Accuracy (%) Mean CV (%) Accuracy (%) 
Whole blood stability (RT) 
(02 h 05 min) 
HQC 1.4827 1.70 99.43 1.5390 2.84 98.18 
LQC 0.0201 2.31 97.57 0.0218 1.92 98.34 
Bench top stability 
(27 h 16 min) 
HQC 2218.64 1.72 98.18 2147.713 2.06 94.92 
LQC 31.346 4.19 104.50 31.957 2.45 106.40 
Auto sampler stability at 10ºC  
(80 h 6 min) 
HQC 2359.579 2.97 104.42 2345.350 1.97 103.66 
LQC 30.542 2.79 101.82 31.709 3.83 105.57 
Five freeze thaw cycles 
(-20±50C)  
HQC 2361.461 2.71 104.50 2368.093 1.80 104.66 
LQC 30.896 4.37 103.00 32.064 4.07 106.76 
Five freeze thaw cycles 
(-70±100C)  
HQC 2214.548 4.81 98.00 2268.334 3.58 100.25 
LQC 28.906 2.65 96.37 30.984 3.57 103.16 
Dry extract stability (RT) 
27 Hrs 5 min 
HQC 2217.044 1.85 98.11 2138.510 1.95 94.52 
LQC 31.131 1.84 103.78 31.700 1.95 105.54 
Post extracted stability (RF) 
27 h 
HQC 2230.552 1.38 98.71 2146.388 2.06 94.86 
LQC 30.887 2.63 102.97 31.507 2.98 104.90 
Coolant Stability 
69 h 51 min 
HQC 2221.800 4.97 98.32 2296.974 3.62 101.52 
LQC 29.311 5.51 97.72 31.221 3.41 103.95 
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samples by centrifugation of samples at 4°C with a 
speed of 3000 RPM for about 10 minutes. The 
samples were processed and analyzed as per the 
analyte specific method procedure. The results are 
presented in Table 6. 
The dry extract stability of DAC and SOF was 
determined (after processing but before adding 
reconstitution solution) during storage in the 
refrigerator (0-10ºC). The six sets of low (LQC) and 
high (HQC) for DAC & SOF were kept for approx. 27 
h 5 min in a refrigerator at 0-10ºC prior to dry extract 
analysis and compared with freshly prepared 
calibration standards and freshly prepared comparison 
(LQC & HQC) samples. The results are presented in 
Table 6. These results showed dry extract stability  
for DAC & SOF during storage in the refrigerator  
(0-10ºC) was approx. 27 h 5 min. 
 
Pharmacokinetic parameters 
In a total 48 subjects study the mean and SD of 
pharmacokinetic parameters estimated for test product 
(A) and reference product (B) were as follows: The 
maximum plasma concentration Cmax of the Test 
product A 1544.780±420.9965 ng/mL while for the 
reference product it was 1581.390±435.8123 ng/mL. 
The mean AUC0-t of DAC was 16967.223±5427.0998 
ng.hr/mL for the DAC (Test Product A) while  
for the reference dose it was found to be 
16916.172±4957.6863 ng.h/mL. The AUC0-∞ was 
found to be 18258.116±5888.8902 ng.hr/mL and 
18332.446±5751.2101 ng. h/mL for the test and 
reference dose regimen respectively. The reference 
and test dosage regimens have tmax values of 1.500 
and 1.250 h respectively and a minimal difference in 
the t1/2 values (10.655 hr and 10.461 hr for the test and 
reference product respectively). The Kel and (AUC0-t/ 
AUC0-inf) *100 values for the test and reference 
product are listed in Table 7. 
For SOF the Cmax was 1816.364 ng/ml and 1582.890 
ng/ml for the test and reference product respectively. 
The Tmax was 0.660 h and 0.830 h for the test and 
reference dosage regimens and little difference was 
observed for the t1/2 values for the test (0.545 h) and 
reference product (0.514). The mean AUC0-t was 
2033.987 ng. h/mL for the test product and 1841.75 ng. 
h/mL for the reference product respectively. The 
AUC0-inf for the test and reference product was 
2045.382 ng. h/mL and 1852.852 ng. h/mL 
respectively. The Kel and (AUC0-t/AUC0-inf)*100 values 
for the test and reference product are listed in Table 8. 
The geometric least squares mean, percentage of 
test product (A) and reference product (B), (A /B) , 
90% confidence intervals, for the log-transformed 
pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf 
for DAC and SOF were summarized in Table 9.  
Table 7 — Pharmacokinetic parameters for DAC in test and reference product under fasting conditions. 
Parameters (Units) Un-transformed Data (Mean ± SD) 
Test Product(A) n=77 Reference Product (B) n=77 
*Tmax (h) 1.500(0.830-4.500) 1.250(0.830-6.000) 
Cmax (ng/mL) 1544.780±420.9965 1581.390±435.8123 
AUC0-t (ng.h/mL) 16967.223±5427.0998 16916.172±4957.6863 
AUC0-inf (ng.h/mL) 18258.116±5888.8902 18332.446±5751.2101 
Kel (1/h) 0.067±0.0126 0.070±0.0143 
t½ (h) 10.655±2.0178 10.461±3.1493 
(AUC0-t/AUC0-inf)*100 93.291±5.6723 93.163±6.9722 
*Median, Minimum and Maximum values reported for Tmax. 
 
Table 8 — Pharmacokinetic parameters for SOF in test and reference product under fasting conditions. 
Parameters (Units) Un-transformed Data (Mean ± SD) 
Test Product(A) n=77 Reference Product (B) n=77 
*Tmax (h) 0.660(0.330-3.500) 0.830(0.250-3.000) 
Cmax (ng/mL) 1816.364±848.2540 1582.890±613.1162 
AUC0-t (ng.h/mL) 2033.987±829.1908 1841.75±640.7657 
AUC0-inf (ng.h/mL) 2045.382±828.8982 1852.852±640.9853 
Kel (1/h) 1.331±0.2587 1.395±0.2577 
t½ (h) 0.545±0.1422 0.514±0.0972 
(AUC0-t/AUC0-inf)*100 99.323±0.4454 99.308±0.4542 
*Median, Minimum and Maximum values reported for Tmax. 
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The ratio of geometric least squares mean for the 
Cmax of test product (A) and reference product (B) 
treatments of log-transformed pharmacokinetic 
parameter Cmax for DAC was 98.06%. The two one-
sided 90% confidence interval for the ratio of the 
geometric least squares mean was found 91.86-104.68 %. 
The ratio of geometric least squares mean of test 
product (A) and reference product (B) treatments of 
log-transformed pharmacokinetic parameter AUC0-t 
was 99.34%. For AUC0-t the two one-sided 90% 
confidence interval for the ratio of the geometric least 
squares mean was found 93.99-105.00. For the log-
transformed pharmacokinetic parameter AUC0-inf the 
ratio of geometric least squares mean of test product 
(A) and reference product (B) treatments was 99.09 % 
and the two one-sided 90% confidence interval for the 
ratio of geometric least squares mean was found 
93.68-104.81 %. In DAC for all the pharmacokinetic 
parameters the 90% confidence interval is within the 
acceptance limits as represented in Table 9. 
For SOF the ratio of geometric least squares mean 
of test product (A) and reference product (B) 
treatments of log-transformed pharmacokinetic 
parameter Cmax and AUC0-t was 111.41%. and 
106.14% respectively. The two one-sided 90% 
confidence interval for the ratio of the geometric least 
squares mean for the Cmax and AUC0-t was found 
100.60 -123.38 % and 99.53-113.19% respectively. In 
case of log-transformed pharmacokinetic parameter 
AUC0-inf the ratio of geometric least squares mean of 
test product (A) and reference product (B) treatments 
of was 106.13 %. The two one-sided 90% confidence 
interval for the ratio of geometric least squares mean 
for AUC0-inf was found 99.59-113.11 %. For SOF also 
all the pharmacokinetic parameters are within the 
acceptance limits of as represented in Table 9. The 
linear and semi log plot of mean plasma concentration 
versus time curves of DAC and SOF after 
administration of test product (A) and reference 
product (B) under fasting conditions are represented 
in Fig. 2 that indicates the test product (A) compared 
to the Reference product (B), met the bioequivalence 
criteria under fasting conditions. 
The study presents the development, validation, and 
clinical application of a novel bioanalytical method of 
DAC and SOF usingLC-MS/MS in the positive 
ionization mode with DAC-13C2D6 and SOF-d6 as the 
respective internal standards.Results from clinical 
studies as well as preliminary real-life data regarding 
the combination of SOF (a nucleotide polymerase 
inhibitor) and DAC, a first-in-class NS5A replication 
complex inhibitor, demonstrate that it is one of the 
most promising antiviral therapies, with once-daily oral 
dosing, a low pill burden, good tolerability, and limited 
drug–drug interactions, in addition to high antiviral 
potency, with 90% sustained virologic response rates. 
This combination has high pangenotypic antiviral 
potency regardless of the severity and patient 
characteristics.In a 24 week extended study outcome 
SOF plus DAC+ribavirin obtained 100% efficacy in 
genotype 3 hepatitis C cirrhosis, with very limited side 
effects
19
. Thus it appeared of interest to develop a 
highly sensitive, reliable and selective bioanalytical 
methods and its application for pharmacokinetic 
measurements and optimization of dosages in clinical 
study. This study exclusively reports the well validated 
method for the simultaneous quantification of DAC 
and SOF and the application of the method to study the 
pharmacokinetic parameters in 48 male subjects. 
During method development an extensive method 
optimization was performed to select the best 
extraction procedure for selective determination of 
DAC and SOF from human plasma. Depending on the 
extraction efficiency SPE was tested on (Strata-X, 30 
mg, 1cc) cartridge for their simultaneous determination 
in human plasma.  
Table 9 — Statistical results for DAC and SOF test and reference products under fasting condition. 
Parameters (Units) Ratio of geometric least squares means Acceptable 
Lower BE limit 
(%) 
Acceptable 
Upper BE limit (%) 
90% Confidence 
limits 
Test product (A) Reference product (B) (A/B)% (A vs. B) 
DAC 
Cmax (ng/mL) 1476.4399 1505.6365 98.06 75.81 131.91 91.86-104.68 
AUC0-t (ng.h/mL) 15978.9751 16084.7272 99.34 80.00 125.00 93.99-105.00 
AUC0-inf (ng.h/mL) 17172.9780 17330.7229 99.09 80.00 125.00 93.68-104.81 
SOF 
Cmax (ng/mL) 1625.4665 1458.9713 111.41 69.83 143.21 100.60 -123.38 
AUC0-t (ng.h/mL) 1847.5201 1740.6457 106.14 80.00 125.00 99.53-113.19 
AUC0-inf (ng.h/mL) 1860.2153 1752.7127 106.13 80.00 125.00 99.59-113.11 
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An Acquity UPLC system (Waters) equipped with 
Waters Xevo TQ MS system consisting of a Gemini 
NX 5µ C18 (50 × 2.0mm) (Phenomenex), a pump 
(Acquity binary sample Manager, Waters), and an 
auto sampler (Acquity sample manager) were used for 
the study. Aliquots of the processed samples (2 µL) 
were injected into the column, which was kept at 
ambient temperature (40 ± 5 ºC). A gradient mobile 
phase consisting 5 mM Ammonium Formate buffer: 
Acetonitrile was used to separate the analytes and 
delivered at a flow rate of 0.300 mL/min after 
severaloptimizations to achieve, adequate response 
and complete separation. All mass parameters were 
suitably optimized to obtain a stable and adequate 
response for the analytes. The difference in retention 
time of SOF and DAC were 1.40± 0.30 and  
2.15± 0.30 mins respectively and for the Internal 




H6) (1.35± 0.30 and 
2.12± 0.30 mins) respectively allowed a good 
separation for both the analytes. Further, use of 
deuterated internal standards helped to compensate 
any variability during extraction and UPLC-MS/MS 
analysis. 
The validation was carried out as per US FDA 
guidelines
20
. The parameters determined were 
selectivity, sensitivity, matrix effect, linearity, 
precision, accuracy, recovery, stability and dilution 
integrity. The selectivity and sensitivity results 
established the method to be selective for both these 
analytes with adequate response. No Matrix effect 
was observed for six different lots of K3-EDTA 
plasma and the blank plasma samples were also 
analyzed to confirm the absence of direct 
interferences. The results of the three P&A batches 
confirm the reproducibility of the method with an 
excellent ruggedness for different analyst and column 
and suggested a suitable method for the quantification 
of DAC and SOF in human plasma. This optimized 
and validated LC–MS method was applied to quantify 
plasma DAC and SOF concentration for a 
bioequivalence study in 48 healthy subjects after oral 
administration of (DAC/SOF) 60 mg /400 mg of 
Mylan laboratories limited, India with daklinza ™ 
(DAC) tablets 60 mg (Bristol-Myers Squibb 
Company, Princeton, NJ 08543, USA) and sovaldi
®
 
(SOF) 400 mg film-coated tablets (Gilead Sciences 
International Ltd. Cambridge cb 216gt United 
Kingdom), under fasting conditions. 
 
Conclusion 
A simple, rapid and sensitive LC-MS/MS assay 
method is described in this paper for the 
quantification of DAC and SOF in human plasma and 
full validation of the method was performed following 
the FDA guidelines. To the best of our knowledge, 
this report is the first one to describe the simultaneous 
quantification of DAC and SOF in human matrix. The 
developed method showed good linearity with 
 
 
Fig. 2 — (a)Linear and (b) Semi log plot of mean plasma concentration versus time curves of DAC after administration of test product 
(T) and reference product (R) under fasting conditions. (c)Linear and (d) Semi log plot of mean plasma concentration versus time curves 
of SOF after administration of test product (T) and reference product (R) under fasting conditions. 
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reproducible and consistent recoveries of DAC and 
SOF from plasma. The method was applied for 
pharmacokinetic studies of DAC and SOF in human’s 
plasma. The developed method with desired precision 
and accuracy could be helpful for the bioequivalence 




DAC: Daclatasvir; SOF: Sofosbuvir; FDA: Food  
and Drug Administration;Cmax: Maximum plasma 
concentration; ICH: International Conference on 
Harmonisation; HPLC: High Performance Liquid 
Chromatography; USA: United State on America; 
LCMS: Liquid Chromatography; Mass Spectrometry; 
K3EDTA: Tripotassium Ethylene Diamine Tetra  
Acetate; BE: Bioequivalence;LLOQ: Lower Limit of 
Quantification; MS: Mass Spectrometry; GS: Gas; DP: 
Clustering Potential; EP: Entrance Potential; 
CE:Collision Energy; CXP: Cell Exit Potential; QC: 
QualityControl, CS: Calibration Standard; WIS: 
Working InternalStandard; HLB: Hydrophilic Lipophilic 
Balance;EMA: European Medicines Agency; LQC: 
Low QC;MQC: Med QC; HQC: High QC; DQC: 
Diluted QC;ULOQ: Upper Limit of Quantification; PB: 
PlasmaBlank; GCP: Good Clinical Practice, CV: Co-
efficientof Variation; SD: Standard Deviation 
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